Home/Pipeline/PROSPER Study Compound

PROSPER Study Compound

Progressive Supranuclear Palsy (PSP)

Phase 2Active

Key Facts

Indication

Progressive Supranuclear Palsy (PSP)

Phase

Phase 2

Status

Active

Company

Ferrer

About Ferrer

Ferrer is a mission-driven, private Spanish pharmaceutical company with a diversified portfolio spanning therapeutics, diagnostics, and vaccines. It is advancing a late-stage clinical pipeline focused on neurological disorders like ALS and Progressive Supranuclear Palsy (PSP), while maintaining a commercial footprint. The company differentiates itself through its strong 'Ferrer for Good' ESG commitment, which is central to its operations and has earned it recognition as one of the World's Most Ethical Companies.

View full company profile

Therapeutic Areas

Neurology Rare Diseases

Other Progressive Supranuclear Palsy (PSP) Drugs

Drug	Company	Phase	Status
Not Specified	New Amsterdam Sciences	Pre-clinical	Active
PREP/PP2A Modulator Program	Polku Therapeutics	Discovery	Active
AZP2006	Alzprotect	Phase 2	Active
Undisclosed Tau Immunotherapy	TauC3 Biologics	Pre-clinical	Active